SOURCE: SECFilings.com

SECFilings.com

November 18, 2016 06:00 ET

Innovus Pharma (INNV) Continues to Execute with Record Q3 '16 Revenue -- SECFilings.com

REDONDO BEACH, CA--(Marketwired - Nov 18, 2016) - SECFilings.com, a leading financial news and information portal offering free real-time public filing alerts, announces the publication of an article examining Innovus Pharmaceuticals' (OTCQB: INNV) recently announced third quarter financial results and the company's outlook moving forward into the new year.

The clear majority of micro-cap pharmaceutical companies are years away from meaningful revenue, but Innovus Pharmaceuticals is a notable exception to the rule with rapidly growing revenue and a robust pipeline. The management seems to be focused on generating sustainable revenues and achieving profitability. During the third quarter, the company reported a 947% year-over-year increase in revenue to a record $1.9 million, as management continues to prove that it can deliver significant shareholder value.

Innovus Pharmaceuticals' Beyond Human Sales and Marketing Platform has become the cornerstone of its revenue growth. Since acquiring Beyond Human in March 2016, the company has experienced 42% monthly growth and gross margins that exceed 80%. The platform reaches between 20 and 30 million potential customers monthly with Beyond Human Testosterone Booster®, Vesele®, Sensum+®, Zestra®, and RecalMax® products.

The Beyond Human platform enables the company to reach millions of potential customers each month and create subscriptions for their products. By doing so, the company can generate a steady flow of recurring revenue rather than one-time sales revenues. The platform also enables the company to cross-sell its other products to the same market and reach an immediate customer base with any future product launches.

If the company continue its 42% compounded growth it might well exceed its anticipated $5M in revenue for 2016 and $15M in revenue for 2017 as it continues to launch new products. In addition, management aims to up-list to the NASDAQ, under the right market conditions, to open the door to institutional investments. After raising $3 million in July 2016, the company remains on solid financial footing when it comes to acquiring more products and increasing its marketing efforts to drive growth.

Follow the link to read the full article: http://analysis.secfilings.com/articles/125-innovus-pharma-innv-continues-to-execute-with-record-q3-16-revenue

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

Contact Information